On 8/12/24, Revance Therapeutics Inc (NASDAQ: RVNC) stock enjoyed a major increase of 87.0%, closing at $6.60. Moreover, trading volume in this advance was exceptionally high at 1983% of normal. Relative to the market the stock has been extremely weak over the last nine months but has risen 106.2% during the last week.
Current PriceTarget Research Rating
RVNC's future returns on capital are forecasted to fall short of the cost of capital. Accordingly, the company is expected to be a modest Value Eraser.
Revance Therapeutics is currently unrated.
Rating Review
The stock is currently unrated.